EMD Serono Research & Development Institute

51 total trials 34 currently recruiting 8 completed

Trial Pipeline

RECRUITING Phase 1

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

NCT07360314

RECRUITING Phase 1

M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors

NCT07166601

RECRUITING Phase 1

Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

NCT06710132

RECRUITING Phase 1

Anti-GD2 ADC M3554 in Advanced Solid Tumors

NCT06641908

RECRUITING

Met Non Small Cell Cancer Registry (MOMENT)

NCT05376891

RECRUITING Phase 1

Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)

NCT05464030

ACTIVE NOT RECRUITING Phase 2

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

NCT06433219

ACTIVE NOT RECRUITING Phase 1

M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)

NCT06421935

ACTIVE NOT RECRUITING Phase 1

Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

NCT05882734

ACTIVE NOT RECRUITING Phase 2

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

NCT05327530

ACTIVE NOT RECRUITING Phase 1

Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)

NCT05396833

ACTIVE NOT RECRUITING Phase 1

Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

NCT04170153

ACTIVE NOT RECRUITING Phase 2

A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

NCT03940703

ACTIVE NOT RECRUITING Phase 3

Avelumab Program Rollover Study

NCT03815643

ACTIVE NOT RECRUITING Phase 2

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

NCT02864992

COMPLETED Phase 3

Bintrafusp Alfa Program Rollover Study

NCT05061823

COMPLETED Phase 1

First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410)

NCT04882917

COMPLETED

The MS-LINK™ Outcomes Study

NCT04735406

COMPLETED Phase 1

M1231 in Participants With Solid Tumors

NCT04695847

COMPLETED Phase 1

Tepotinib Hepatic Impairment Trial

NCT03546608

COMPLETED

Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes

NCT03284970

COMPLETED Phase 1

First-in-Human Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy

NCT02644278

COMPLETED Phase 3

Oral Cladribine in Early Multiple Sclerosis (MS)

NCT00725985

What the Pipeline for EMD Serono Research & Development Institute Shows

According to the ClinicalTrials.gov registry, EMD Serono Research & Development Institute is linked to 51 US clinical trials across every stage of research activity. Of those, 34 studies are currently recruiting — about 67% of the sponsor's indexed portfolio — and 8 are already marked complete, representing roughly 16% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

The phase mix for EMD Serono Research & Development Institute reports 3 late-stage studies (Phase 3 and Phase 4 combined) and 45 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

The top therapeutic focus area indexed for EMD Serono Research & Development Institute is Advanced Solid Tumor with 4 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial